GSA Capital Partners LLP Raises Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Posted by admin on Aug 26th, 2022

GSA Capital Partners LLP raised its stake in Cryoport, Inc. (NASDAQ:CYRX – Get Rating) by 228.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,706 shares of the consumer goods maker’s stock after buying an additional 9,534 shares during the quarter. GSA Capital Partners LLP’s holdings in Cryoport were worth $478,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its holdings in Cryoport by 132.3% in the 1st quarter. First Horizon Advisors Inc. now owns 1,080 shares of the consumer goods maker’s stock valued at $38,000 after buying an additional 615 shares in the last quarter. Pinebridge Investments L.P. purchased a new stake in Cryoport in the 4th quarter valued at $77,000. Commonwealth Equity Services LLC purchased a new stake in Cryoport in the 4th quarter valued at $244,000. Ensign Peak Advisors Inc purchased a new stake in Cryoport in the 4th quarter valued at $355,000. Finally, HighTower Advisors LLC purchased a new stake in Cryoport in the 4th quarter valued at $381,000.

Insiders Place Their Bets

In other Cryoport news, Director Richard J. Berman sold 2,708 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $43.05, for a total transaction of $116,579.40. Following the sale, the director now owns 107,203 shares in the company, valued at approximately $4,615,089.15. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Cryoport news, Director Richard J. Berman sold 2,708 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $43.05, for a total transaction of $116,579.40. Following the sale, the director now owns 107,203 shares in the company, valued at approximately $4,615,089.15. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert J. Hariri sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $43.29, for a total value of $86,580.00. Following the sale, the director now owns 7,911 shares in the company, valued at approximately $342,467.19. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on CYRX. Roth Capital dropped their target price on Cryoport from $90.00 to $67.00 in a report on Tuesday, May 3rd. B. Riley decreased their price target on Cryoport from $61.00 to $55.00 in a research note on Tuesday, May 17th. BTIG Research decreased their price target on Cryoport from $95.00 to $60.00 in a research note on Friday, May 6th. KeyCorp decreased their price target on Cryoport from $92.00 to $52.00 in a research note on Friday, May 6th. Finally, Needham & Company LLC upped their price target on Cryoport from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, July 12th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cryoport currently has a consensus rating of “Buy” and a consensus price target of $61.33.

Cryoport Price Performance

CYRX opened at $39.91 on Friday. The stock’s 50-day moving average price is $35.49 and its 200 day moving average price is $31.50. Cryoport, Inc. has a 12-month low of $19.82 and a 12-month high of $86.30. The company has a current ratio of 14.21, a quick ratio of 13.69 and a debt-to-equity ratio of 0.73. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -6.46 and a beta of 1.13.

Cryoport (NASDAQ:CYRX – Get Rating) last posted its earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Cryoport had a negative return on equity of 14.43% and a negative net margin of 125.96%. The firm had revenue of $64.20 million for the quarter, compared to analyst estimates of $64.58 million. During the same period in the previous year, the company posted ($0.16) EPS. Cryoport’s revenue was up 14.2% on a year-over-year basis. As a group, sell-side analysts expect that Cryoport, Inc. will post -0.77 earnings per share for the current year.

Cryoport Profile

(Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.